|
|
Article: Genentech Provides Business Update at Annual Investment Community Meeting.
- Article from:
- Business Wire
- Article date:
- March 14, 2008
|
Copyright informationCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) is providing investors today with an overview of recent developments in its business, including highlights from the research, development and commercial areas.
"We remain focused on conducting excellent science and translating our scientific understanding into important new medicines that may benefit patients with serious diseases," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "We are pleased with the progress of our pipeline. We currently have 13 new molecular entities in Phase I, six of which are in immunology or tissue growth and repair. Additionally, we have six new ...
Related newspaper, magazine, and journal articles:
|